Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 14 | 2023 | 16073 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2023 | 16327 | 0.300 |
Why?
|
| Doxorubicin | 4 | 2021 | 3060 | 0.280 |
Why?
|
| Triple Negative Breast Neoplasms | 3 | 2023 | 1307 | 0.230 |
Why?
|
| Receptors, Estrogen | 4 | 2020 | 2131 | 0.210 |
Why?
|
| Receptor, ErbB-2 | 7 | 2020 | 2629 | 0.210 |
Why?
|
| Polyethylene Glycols | 3 | 2021 | 636 | 0.200 |
Why?
|
| Metformin | 2 | 2019 | 391 | 0.200 |
Why?
|
| Argininosuccinate Synthase | 1 | 2021 | 54 | 0.200 |
Why?
|
| Hydrolases | 1 | 2021 | 132 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 5156 | 0.180 |
Why?
|
| Receptors, Progesterone | 3 | 2020 | 1413 | 0.170 |
Why?
|
| Postmenopause | 2 | 2019 | 379 | 0.170 |
Why?
|
| Bevacizumab | 3 | 2017 | 948 | 0.150 |
Why?
|
| Overweight | 2 | 2019 | 492 | 0.150 |
Why?
|
| Sirolimus | 4 | 2017 | 832 | 0.140 |
Why?
|
| Androstadienes | 2 | 2019 | 172 | 0.140 |
Why?
|
| Metaplasia | 2 | 2015 | 388 | 0.130 |
Why?
|
| Everolimus | 4 | 2020 | 425 | 0.130 |
Why?
|
| Epothilones | 1 | 2015 | 55 | 0.120 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 2657 | 0.120 |
Why?
|
| Bone Density Conservation Agents | 1 | 2016 | 203 | 0.120 |
Why?
|
| Diphosphonates | 1 | 2016 | 266 | 0.120 |
Why?
|
| Obesity | 2 | 2019 | 2983 | 0.110 |
Why?
|
| Mesoderm | 1 | 2015 | 407 | 0.110 |
Why?
|
| Dasatinib | 1 | 2016 | 879 | 0.100 |
Why?
|
| Taxoids | 1 | 2015 | 992 | 0.100 |
Why?
|
| Thiazolidinediones | 1 | 2012 | 150 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2015 | 1113 | 0.090 |
Why?
|
| Imidazoles | 1 | 2016 | 1035 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2021 | 6269 | 0.090 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 733 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2015 | 1000 | 0.090 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2014 | 694 | 0.080 |
Why?
|
| Epirubicin | 2 | 2020 | 157 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2023 | 1559 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 1 | 2012 | 718 | 0.070 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2014 | 1225 | 0.070 |
Why?
|
| Middle Aged | 14 | 2021 | 89661 | 0.070 |
Why?
|
| Proportional Hazards Models | 4 | 2017 | 5094 | 0.070 |
Why?
|
| Female | 17 | 2023 | 147624 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2016 | 10641 | 0.070 |
Why?
|
| Adult | 12 | 2021 | 80872 | 0.070 |
Why?
|
| Survival Rate | 4 | 2021 | 12475 | 0.060 |
Why?
|
| Paclitaxel | 3 | 2020 | 2061 | 0.060 |
Why?
|
| Aged | 12 | 2020 | 73018 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 3376 | 0.060 |
Why?
|
| Trastuzumab | 2 | 2020 | 719 | 0.060 |
Why?
|
| Neoplasms | 2 | 2021 | 15797 | 0.060 |
Why?
|
| Antineoplastic Agents | 3 | 2015 | 14558 | 0.060 |
Why?
|
| Neoplasm Metastasis | 4 | 2015 | 5250 | 0.060 |
Why?
|
| Fluorouracil | 2 | 2020 | 1968 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2015 | 3968 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2012 | 6221 | 0.050 |
Why?
|
| Prognosis | 5 | 2020 | 22348 | 0.050 |
Why?
|
| Humans | 17 | 2023 | 270969 | 0.050 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2020 | 38 | 0.050 |
Why?
|
| Ketones | 1 | 2020 | 56 | 0.050 |
Why?
|
| Furans | 1 | 2020 | 106 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 2342 | 0.040 |
Why?
|
| Cyclophosphamide | 2 | 2020 | 3150 | 0.040 |
Why?
|
| Carcinoma | 1 | 2011 | 2602 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 15255 | 0.040 |
Why?
|
| Disease-Free Survival | 3 | 2015 | 10092 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 4458 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2020 | 34335 | 0.040 |
Why?
|
| Elafin | 1 | 2017 | 35 | 0.040 |
Why?
|
| Maryland | 1 | 2015 | 50 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 166 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 5021 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2015 | 219 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 608 | 0.030 |
Why?
|
| Mastectomy | 1 | 2020 | 1569 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2016 | 480 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2015 | 525 | 0.030 |
Why?
|
| Cholesterol | 1 | 2016 | 677 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2016 | 703 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 552 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2019 | 13336 | 0.030 |
Why?
|
| Carboplatin | 1 | 2015 | 844 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 3512 | 0.020 |
Why?
|
| Time Factors | 2 | 2015 | 13261 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 2081 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2020 | 39724 | 0.020 |
Why?
|
| Breast | 1 | 2016 | 1361 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 1806 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 13883 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 2302 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 3218 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 1710 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 1583 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2017 | 12145 | 0.020 |
Why?
|
| Young Adult | 2 | 2015 | 22268 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 5015 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 30845 | 0.010 |
Why?
|
| Texas | 1 | 2015 | 6489 | 0.010 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 1384 | 0.010 |
Why?
|
| Gene Expression | 1 | 2012 | 3574 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 2717 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 4921 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 5298 | 0.010 |
Why?
|
| Male | 2 | 2021 | 127769 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 7711 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 5228 | 0.010 |
Why?
|
| Risk Factors | 1 | 2015 | 18036 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 9065 | 0.010 |
Why?
|
| United States | 1 | 2015 | 16325 | 0.010 |
Why?
|